Biodegradable PLGA85/15 nanoparticles as a delivery vehicle for Chlamydia trachomatis recombinant MOMP-187 peptide

Nanotechnology

Volumn 23, Issue 32, 2012, Pages

  Taha, Murtada A ^a   Singh, Shree R ^a   Dennis, Vida A ^a  

^a ALABAMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLAMYDIA TRACHOMATIS; CYTOKINES; DELIVERY SYSTEMS; DELIVERY VEHICLE; DOSE RESPONSE; ENCAPSULATION EFFICIENCY; EUKARYOTIC CELLS; IN-VITRO; MAJOR OUTER MEMBRANE PROTEINS; PHYSIOCHEMICAL CHARACTERIZATION; POLY(D , L-LACTIC-CO-GLYCOLIC ACID); PRODUCTION LEVEL; SLOW RELEASE; THERMALLY STABLE; TRANSMISSION ELECTRON; VIABLE CELLS;

ATOMIC FORCE MICROSCOPY; BIOLOGICAL MEMBRANES; DATA ENCAPSULATION; DIFFERENTIAL SCANNING CALORIMETRY; INFRARED SPECTROSCOPY; LOADING; MACROPHAGES; NITRIC OXIDE; PEPTIDES; VACCINES; WELL STIMULATION; ZETA POTENTIAL;

ENCAPSULATION;

DRUG CARRIER; INTERLEUKIN 12; INTERLEUKIN 6; LACTIC ACID; NANOPARTICLE; NITRIC OXIDE; OMPA OUTER MEMBRANE PROTEINS; OUTER MEMBRANE PROTEIN; PEPTIDE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; RECOMBINANT PROTEIN; RECOMBINANT VACCINE;

ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; CELL LINE; CELL SURVIVAL; CHEMISTRY; CHLAMYDIA TRACHOMATIS; DOSE RESPONSE; DRUG EFFECT; FLUORESCENCE MICROSCOPY; IMMUNOLOGY; METABOLISM; MOUSE; PARTICLE SIZE;

ANALYSIS OF VARIANCE; ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; CELL LINE; CELL SURVIVAL; CHLAMYDIA TRACHOMATIS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG CARRIERS; INTERLEUKIN-12; INTERLEUKIN-6; LACTIC ACID; MICE; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; NITRIC OXIDE; PARTICLE SIZE; PEPTIDES; POLYGLYCOLIC ACID; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC;

EID: 84864410996     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/23/32/325101     Document Type: Article

References (52)

1. Singh S R, Hulett K, Pillai S R, Dennis V A, Oh M K and Scissum-Gunn K 2006 Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection Vaccine 24 1213-24 (Pubitemid 43204503)
2. Yu H, Jiang X, Shen C, Karunakaran K B and Brunham R C 2009 Novel Chlamydia muridarum T cell antigens induce protective immunity against lung and genital tract infection in murine models J. Immunol. 182 1602-8
3. WHO 1996 Global Prevalence and Incidence of Selected Curable Sexually Transmitted Diseases: Overview and Estimates (Geneva: World Health Organization)
4. Peeling R W and Brunham R C 1996 Chlamydiae as pathogens: new species and new issues Emerg. Infect. Diseases 2 307-19 (Pubitemid 126445001)
5. Westrom L J R, Joesoef R, Reynolds G, Hagdu A and Thompson S E 1992 Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results Sex. Transm. Dis. 4 185-92
6. Pal S, Theodor I, Peterson E M and de la Maza L M 1997 Immunization with an a cellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge Infect. Immun. 65 3361-9 (Pubitemid 27342422)
7. Brunham R C and Rey-Ladino J 2005 Immunology of Chlamydia infection; implications for a Chlamydia trachomatis vaccine Nature 5 149-61 (Pubitemid 40208904)
8. Igietseme J U, Black C M and Caldwell H D 2002 Chlamydia vaccines: strategies and status BioDrugs 16 19-35 (Pubitemid 34303965)
9. Pal S and Peterson E M 2006 Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines can induce partial protection in a mouse model against a genital challenge Vaccine 24 766-75 (Pubitemid 43190083)
10. Su H, Parnell M and Caldwell H D 1995 Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against genital tract infection Vaccine 13 1023-32
11. Taha M A, Singh S R, Hulett K, Pillai S R, Agee R and Dennis V A 2011 A peptide containing T-Cell epitopes of Chlamydia trachomatis recombinant MOMP induces systemic and mucosal antibody responses in mice W. J. V. 1 138-47
12. Beagley K W and Timms P 2000 Chlamydia trachomatis infection: incidence, health costs and prospects for vaccine development J. Reprod. Immunol. 48 47-68
13. Toye B, Zhong G M, Peeling R and Brunham R C 1990 Immunologic characterization of a cloned fragment containing the species-specific epitope from the major outer membrane protein of Chlamydia trachomatis Infect. Immun. 58 3909-13
14. Eko F O et al 2004 A novel recombinant multisubunit vaccine against Chlamydia J. Immunol. 173 3375-82 (Pubitemid 39142047)
15. Dai C and Wang B 2005 Microencapsulation peptide and protein drugs delivery system Colloid Surface B 41 117-20 (Pubitemid 40298824)
16. Behera T and Nanda P K 2010 Parenteral immunization of fish, Labeo rohita with poly d,l-lactide-co-glycolic acid (PLGA) encapsulated antigen microparticles promotes innate and adaptive immune responses Fish Shellfish Immun. 28 320-5
17. Peek L J and Middaugh C R 2008 Nanotechnology in vaccine delivery Adv. Drug Deliv. Rev. 60 915-28
18. Sandhya M, Srinivas P and Sadanandam M 2010 Nanoparticulate systems and other novel approaches in the diagnosis, prevention and treatment of hiv/aids Int. J. Pharm. Sci. 2 738-49
19. Kumari A, Yadav S K and Yadav S C 2010 Biodegradable polymeric nanoparticles based drug delivery systems Colloid Surface B 75 1-18
20. Makadia H K and Siegel S J 2011 Poly lactic-co-glycolic acid (PLGA) as biodegradablecontrolled drug delivery carrier Polymers 3 1377-97
21. Gutierro I, Hernández R M, Igartua M, Gascón A R and Pedraz J L 2002 Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres Vaccine 21 67-77 (Pubitemid 35351352)
22. Faisant N, Akiki J, Siepmann F, Benoit J P and Siepmann J 2006 Effects of the type of release medium on drug release from PLGA-based microparticles: experiment and theory Int. J. Pharm. 314 189-97
23. Luzardo-Alvarez A, Blarer N, Peter K, Romero J F, Reymond C, Corradin G and Gander B 2005 Biodegradable microspheres alone do not stimulate murine macrophages in vitro, but prolong antigen presentation by macrophages in vitro and stimulate a solid immune response in mice J. Control. Release 109 62-76 (Pubitemid 41737253)
24. Waeckerle-Men Y and Groettrup M 2005 PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines Adv. Drug Deliv. Rev. 57 475-82 (Pubitemid 39550972)
25. Waeckerle-Men Y, Gander B and Groettrup M 2005 Delivery of tumor antigens to dendritic cells using biodegradable microspheres Method Mol. Med. 109 35-46
26. Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J and Lavasanifar A 2008 Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity Vaccine 26 5046-57
27. Newman K D, Samuel J and Kwon G 1998 Ovalbumin peptide encapsulated in poly (D, L -lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response J. Control. Release 54 49-59 (Pubitemid 28255237)
28. Thomas C, Rawat A, Hope-Weeks L and Ahsan F 2011 Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine Mol. Pharm. 8 405-15
29. Cruz L J, Tacken P J, Fokkink R, Joosten B, Stuart M C, Albericio F, Torensma R and Figdor C G 2010 Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro J. Control. Release 144 118-26
30. Saini V, Jain V, Sudheesh M S, Jaganathan K S, Murthy P K and Kohli D V 2011 Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen Int. J. Pharm. 408 50-7
31. Bouissou C, Potter U, Altroff H, Mardon H and van der Walle C 2004 Controlled release of the fibronectin central cell binding domain from polymeric microspheres J. Control. Release 95 557-66 (Pubitemid 38340505)
32. Boyoglu S, Vig K, Pillai S, Rangari V, Dennis V A, Khazi F and Singh S R 2009 Enhanced delivery and expression of a nanoencapsulated DNA vaccine vector for respiratory syncytial virus Nanomedicine 5 463-72
33. Ravi Kumar M N, Bakowsky U and Lehr C M 2004 Preparation and characterization of cationic PLGA nanospheres as DNA carriers Biomaterials 25 1771-7 (Pubitemid 38102253)
34. Chong C S, Cao M, Wong W W, Fischer K P, Addison W R, Kwon G S, Tyrrell D L and Samuel J 2005 Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery J. Control. Release 102 85-99 (Pubitemid 40093778)
35. Clawson C et al 2010 Delivery of a peptide via poly (D, L-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity Nanomedicine 6 651-61
36. Blanco D and Alonso M J 1998 Protein encapsulation and release from poly (lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants Eur. J. Pharm. Biopharm. 45 285-94 (Pubitemid 28270817)
37. Jain A K, Swarnakar N K, Godugu C, Singh R P and Jain S 2011 The effect of the oral adminstration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen Biomaterials 32 503-15
38. Gupta H, Aqil M, Khar R K, Ali A, Bhatnagar A and Mittal G 2010 Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery Nanomedicine 6 324-33
39. Mu L and Feng S S 2003 A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS J. Control. Release 86 33-48 (Pubitemid 35469120)
40. Sahana B, Santra K, Basu S and Mukherjee B 2010 Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in vitro evaluation Int. J. Nanomed. 5 621-30
41. Waeckerle-Men Y, Allmen E U, Gander B, Scandella E, Schlosser E, Schmidtke G, Merkle H P and Groettrup M 2006 Encapsulation of proteins and peptides into biodegradable poly(d,l-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells Vaccine 24 1847-57 (Pubitemid 43238266)
42. Duncan G, Jess T J, Mohamed F, Price N C, Kelly S M and van der Walle C F 2005 The influence of protein solubilisation, conformation and size on the burst release from poly(lactide-co-glycolide) microspheres J. Control. Release 110 34-48 (Pubitemid 41713929)
43. Rouse J J, Mohamed F and van der Walle C F 2007 Physical ageing and thermal analysis of PLGA microspheres encapsulating protein or DNA Int. J. Pharm. 339 112-20 (Pubitemid 46977596)
44. Kariminia A G, Khatami S K, Zowghi E and Ardestani S K 2002 Study of interleukin-10 and interleukin-12 productions in response to lipopolysaccharides extracted from two different Brucella strains Comp. Immunol. Microbiol. Infect. Dis. 25 85-93 (Pubitemid 34126509)
45. Stevanovic M, Maksin T, Petković J, Filipič M and Uskoković D 2009 An innovative, quick and convenient labeling method for the investigation of pharmacological behavior and the metabolism of poly (d,l-lactide-co-glycolide) nanospheres Nanotechnology 20 335102
46. Gupta R, Srivastava P, Vardhan H, Salhan S and Mittal A 2009 Host immune responses to chlamydial inclusion membrane proteins B and C in Chlamydia trachomatis infected women with or without fertility disorders Reprod. Biol. Endocrinol. 7 38
47. Watford W T, Moriguchi M, Morinobu A and OShea J J 2003 The biology of IL-12: coordinating innate and adaptive immune responses Cytokine Growth Factor Rev. 14 361-8 (Pubitemid 37099449)
48. Boyaka P N and McGhee J R 2001 Cytokines as adjuvants for the induction of mucosal immunity Adv. Drug Deliv. Rev. 51 71-9 (Pubitemid 32763073)
49. Williams D M, Grubbs B G, Darville T, Kelly K and Rank R G 1998 Role for Interleukin-6 in host defense against murine Chlamydia trachomatis infection Infect. Immun. 66 4564-7 (Pubitemid 28402746)
50. Chen B, Stout R and Campbell W F 1996 Nitric oxide production: a mechanism of Chlamydia trachomatis inhibition in interferon-gamma-treated RAW264.7 cells FEMS Immunol. Med. Microbiol. 14 109-20 (Pubitemid 26185022)
51. Khatsenko O G, Barteneva N S, de la Maza L M and Kikkawa Y 1998 Role of nitric oxide in the inhibition of cytochrome P450 in the liver of mice infected with Chlamydia trachomatis Biochem. Pharmacol. 55 1835-42 (Pubitemid 28305266)
52. Igietseme J U 1996 The molecular mechanism of T-cell control of Chlamydia in mice: role of nitric oxide Immunology 87 1-8 (Pubitemid 26029485)